Azelis India acquires’s S Zhaveri Pharmakem distribution business

S.Zaveri Pharmakem established in 1951, is one of the India’s leading supplier of pharmaceutical raw materials and chemicals, happilly announced that their distribution business was completely acquired by Azelis, a leading distributor of speciality chemicals and food ingredients. With this association both the companies will be benefitted in the pharmaceuticals market of India.

Ms. Uma Javeri MD of S.Zaveri Pharmachem said, “Becoming part of such a reputable and big international player will not only provide continuity and security of our distribution business but also additional expertise, infrastructure and growth opportunities. All of those are very important to us and we are thrilled about the next phase in our company history. We have known Azelis for a while, we have great respect for one another, our values and ethos are shared so we are convinced that this was the right move.”

Laurent Nataf, CEO & President, Azelis Asia Pacific, said, “The Indian pharmaceutical industry has grown dramatically over the last 20 years, making it one of the most established exporters of pharmaceuticals, particularly generics. This growth is projected to continue both domestically and internationally. Establishing a strong presence in the pharmaceutical market in India is therefore essential for a distributor like Azelis and we are very excited to have found such a good partner, which will serve as a very good platform to further expand our pharma activities in India. S Zhaveri has an excellent reputation in the market, a unique set of principals and a very knowledgeable team with strong expertise in excipients.”

Aparna Khurana, Managing Director Azelis India, adds, “Azelis and S. Zhaveri’s distribution businesses are highly complementary. The Indian excipient market is outpacing the global growth rate. Here in India, we have favourable raw materials and labour environment coupled with quick adaptability of suppliers to new technology, which makes us a perfect and thriving ground for the industry. An acquisition in the pharma business is, therefore, a significant move for us. We expect that the addition of S. Zhaveri will help us strengthen the relationship with some of our strategic principals and open up many new opportunities.”

PRNewswire